Stevens Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Stevens Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-10,292	Closed	-$79K	–	1210
2016 Q1	$79K	Sell	10,292 -14,788	-59%	-$108K	﹤0.01%	835
2015 Q4	$271K	Buy	+25,080	New	+$228K	0.01%	722
2015 Q3	–	Sell	-24,873	Closed	-$220K	–	1319
2015 Q2	$220K	Buy	+24,873	New	+$235K	0.01%	849
2014 Q4	–	Sell	-20,308	Closed	-$203K	–	1319
2014 Q3	$203K	Sell	20,308 -548	-3%	-$5.09K	0.01%	855
2014 Q2	$158K	Buy	+20,856	New	+$83.2K	﹤0.01%	958

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stevens Capital Management's ACHN Position: Q2 2016 in Review

Stevens Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q2 2016, closing a stake of 10,292 shares — an estimated $79K sold.

Stevens Capital Management first reported a position in ACHN in Q2 2014 and held it in 5 quarters. The position peaked at $271K in Q4 2015. 147 funds tracked by Wall St. Rank hold ACHN as of Q2 2016.

Stevens Capital Management reported no remaining Achillion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Stevens Capital Management sold 10,292 Achillion Pharmaceuticals shares in Q2 2016, an estimated $79K.
Stevens Capital Management first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 5 quarters.
Stevens Capital Management's Achillion Pharmaceuticals position peaked at $271K in Q4 2015.
147 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2016.

Based on Stevens Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.